Drugs / Aescine
Aescine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06709079 | Dec 2024 → Dec 2025 overdue | allergic rhinitis | Cheng Lei | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aescine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06709079 ↗ |
| Known as | Aescine Sodium | “Preoperatively, patients with AR were given 2 tablets of Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals) to be taken after meals, once in the morning and once in the...” NCT06709079 ↗ |
| Known as | Aescine Sodium Tablets | “Preoperatively, patients with AR were given 2 tablets of Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals) to be taken after meals, once in the morning and once in the...” NCT06709079 ↗ |
| Known as | Ocai | “Preoperatively, patients with AR were given 2 tablets of Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals) to be taken after meals, once in the morning and once in the...” NCT06709079 ↗ |